Hepcidin and Glucose Metabolism

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-45
SponsorSwiss Federal Institute of Technology

About this trial

Gestational diabetes mellitus (GDM), defined as hyperglycemia with blood glucose values above normal but below those diagnostic of DM, and iron deficiency (ID) with or without anemia (IDA) are common during pregnancy. Both disease patterns are associated with an increased risk of complications during pregnancy and at delivery and may have a variety of negative effects on different aspects of child development. Thus, GDM and ID/IDA during pregnancy should be prevented.

Whether iron supplementation with high oral doses acutely increases hepcidin during pregnancy, and whether this acute iron-induced increase in hepcidin decreases insulin sensitivity, is uncertain.

Eligibility criteria

Qualifiers

week of pregnancy 24-28

pre-pregnancy BMI <27.5kg/m2

singleton pregnancy

Hb > 8.0 g/dl

Disqualifiers

iron infusion within the past 6 months

severely anemic Hb<8.0g/dl

acute or chronic disease

long-term medication

Trial design

Treatments tested in this trial

  • 100mg iron fumarate
  • Burgerstein Schwangerschaft & Stillzeit

Treatment groups

30 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Swiss Federal Institute of Technology

Lead sponsor

University Hospital, Zürich

Collaborator